[1]裴亚欣,刘向玲,宋子宣,等.康柏西普联合睫状体冷凝和小梁切除术治疗晚期新生血管性青光眼[J].眼科新进展,2020,40(9):875-878.[doi:10.13389/j.cnki.rao.2020.0199]
　PEI Yaxin,LIU Xiangling,SONG Zixuan,et al.Conbercept combined with trabeculectomy and cyclocryotherapy for advanced neovascular glaucoma[J].Recent Advances in Ophthalmology,2020,40(9):875-878.[doi:10.13389/j.cnki.rao.2020.0199]
点击复制

康柏西普联合睫状体冷凝和小梁切除术治疗晚期新生血管性青光眼/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年9期
页码:
875-878
栏目:
应用研究
出版日期:
2020-09-05

文章信息/Info

Title:
Conbercept combined with trabeculectomy and cyclocryotherapy for advanced neovascular glaucoma
作者:
裴亚欣; 刘向玲; 宋子宣; 梁晓洁; 王昕
453003　河南省新乡市，新乡医学院第三临床学院 (裴亚欣，梁晓洁，王昕)；453003　河南省新乡市，新乡医学院第三附属医院眼科(刘向玲，宋子宣)
Author(s):
PEI Yaxin1; LIU Xiangling2; SONG Zixuan2; LIANG Xiaojie1; WANG Xin1
1.The Third Clinical College of Xinxiang Medical University,Xinxiang 453003,Henan Province,China
2.Department of Ophthalmology，the Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003,Henan Province,China
关键词:
康柏西普; 小梁切除术; 睫状体冷凝术; 新生血管性青光眼
Keywords:
Conbercept;  trabeculectomy;  cyclocryotherapy;  neovascular glaucoma
分类号:
R775.3
DOI:
10.13389/j.cnki.rao.2020.0199
文献标志码:
A
摘要:
目的　观察康柏西普联合睫状体冷凝和小梁切除术综合治疗对晚期新生血管性青光眼（NVG）的短期疗效。方法　选取新乡医学院第三附属医院眼科二病区2017年1月至2018年12月收治的晚期NVG患者23例23眼，均于康柏西普玻璃体内注射5~7 d后，行睫状体冷凝和小梁切除术联合治疗，术后随访6个月，观察手术成功率、眼压控制效果、抗青光眼药物使用情况及并发症发生情况。结果　末次随访时，手术成功率为91.30%。注药后3 d患眼眼压为（35.16±5.15）mmHg（1 kPa=7.5 mmHg），明显低于注药前（42.21±6.72）mmHg;术后7 d、1个月、3个月、6个月眼压分别为（13.51±3.96）mmHg、（14.84±5.81）mmHg、（15.85±4.16）mmHg、（16.01±4.41）mmHg,明显低于术前（37.18±5.77）mmHg，差异均具有统计学意义（均为P<0.05）。术后7 d及1个月，使用3~5种抗青光眼药物者的比例分别为65.22%、43.48%，与术前的91.30%相比明显降低，差异均具有统计学意义（均为P<0.05）；术后3个月和6个月，使用2种抗青光眼药物者的比例均为4.35%，不再使用抗青光眼药物者的比例均为95.65%。末次随访时，1眼眼球萎缩，1眼并发大泡性角膜病变，余均未见其他严重并发症发生。结论　康柏西普联合睫状体冷凝和小梁切除术治疗晚期NVG手术成功率较高，能显著减少抗青光眼药物的使用和降低眼压，值得基层医院推广。
Abstract:
Objective　To observe the efficacy and safety of Conbercept combined with trabeculectomy and cyclocryotherapy in the treatment of advanced neovascular glaucoma (NVG).Methods　Totally 23 eyes of 23 NVG patients from January 2017 to December 2018 were selected from the Second Department of Ophthalmology of the Third Affiliated Hospital of Xinxiang Medical University, and all patients were treated by trabeculectomy and cyclocryotherapy for 5-7 days after intravitreal injection of Conbercept. The follow-up period was six months after surgery. The success rate of operation, intraocular pressure control effect, the use of anti-glaucoma drugs and postoperative complications were observed.Results　At the last follow-up, the success rate of operation was 91.30%; the intraocular pressure was (35.16±5.15) mmHg (1 kPa=7.5 mmHg), significantly lower than that before injection ［(42.21±6.72) mmHg］. The intraocular pressure was (13.51±3.96) mmHg, (14.84±5.81) mmHg, (15.85±4.16) mmHg, (16.01±4.41) mmHg on day 7, 1 month, 3 months, and 6months, respectively, significantly lower than that before injection ［(37.18±5.77) mmHg］, and the difference was statistically significant (all P<0.05). After 7 days and 1 month, the proportion of using 3-5 kinds of anti-glaucoma drugs was 65.22% and 43.48% respectively, which was significantly lower than that before operation（91.30%）, and the difference was statistically significant (P<0.05). After 3 months and 6 months, the proportion of using 2 kinds of anti-glaucoma drugs was 4.35%, and the proportion of not taking anti-glaucoma drugs was 95.65%. At the last follow-up, 1 eye had atrophy of eyeball, 1 eye had bullous keratopathy, and no other serious complications were found.Conclusion　Conbercept combined with trabeculectomy and cyclocryotherapy for neovascular glaucoma has a high success rate of operation and can significantly reduce the use of anti-glaucoma drugs and intraocular pressure, which is worthy of promotion in primary hospitals.

参考文献/References:

［1］ANDREAS K,KOSTANTINA G,MIKROPOULOS D G,ARRANZ-MARQUEZ E,ATHANASOPOULOS G P,TEUS M A,et al.Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma［J］.Expert Opin Biol Ther,2018,18(6):719-724.
［2］　赵明威.新生血管性青光眼治疗面临的临床问题与思考［J］.中华实验眼科杂志,2016,34(7):577-579.
ZHAO M W.Clinical problems and thoughts on the treatment of neovascular glaucoma［J］.Chin J Exp Ophthalmol,2016,34(7):577-579.
［3］　BITELI L G,PRATA T S,GRACITELLI C P,KANADANI F N,VILLAS BOAS F,HATANAKA M,et al.Evaluation of the efficacy and safety of the new Susanna glaucoma drainage device in refractory glaucomas:Short-term results［J］.J Glaucoma,2017,26(4):356.
［4］　孙怡,赵海霞,关文英.新生血管性青光眼研究进展［J］.临床和实验医学杂志,2016,13(13):1344-1345.
SUN Y,ZHAO H X,GUAN W Y.Research progress of neovascular glaucoma［J］.J Clin Exp Med,2016,13(13):1344-1345.
［5］　邵毅.青光眼诊断与治疗规范——2017年英国专家共识解读［J］.眼科新进展,2018,38(11):1001-1004.
SHAO Y.Standardized glaucoma treatment:Interpretation of 2017 diagnostic and management guidelines of glaucoma by the British National Institute for Health and Care Excellence(NICE)［J］.Rec Adv Ophthalmol,2018,38(11):1001-1004.
［6］　SONALI T N,PAUL T.Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma［J］.Ophthalmic Surg Lasers Imaging Retina,2015,46(2):201-207.
［7］　乔春艳,邵蕾,许欣悦,杜秀娟,杨晓晗,曹凯,等.2002-2016年北京同仁医院新生血管性青光眼原发病因及治疗方式的变化趋势［J］.眼科,2019,28(1):11-16.
QIAO C Y,SHAO L,XU X Y,DU X J,YANG X H,CAO K,et al.Etiological and clinical therapeutic changes trend of neovascular glaucoma in Beijing Tongren Hospital from 2002 to 2016［J］.Ophthalmol CHN,2019,28(1):11-16.
［8］　LI X J,YANG X P,LI Q M,WANG Y Y,LYU X B.Ranibizumab plus combined surgery for treatment of neovascular glaucoma with vitreous hemorrhage［J］.Chin Med J (Engl),2015,128(15):2078-2083.
［9］　刘红,秦平.玻璃体腔内注射Avastin联合睫状体光凝治疗新生血管性青光眼［J］.新乡医学院学报,2013,30(3):216-217,220.
LIU H,QIN P.Intravitreal injection of Avastin combined with cyclophotocoagulation for neovascular glaucoma［J］.J Xin-xiang Med Univ,2013,30(3):216-217,220.
［10］　LAN L,XU Y,ZHU H,WANG X.Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma:A assessment of efficacy and complications［J］.BMC Ophthalmology,2016,16(1):1-7.
［11］　SUN J T,LIANG H J,AN M,WANG D B.Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma［J］.Int J Ophthalmol,2017,10(3):400
［12］　罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼［J］.眼科新进展,2016,36(11):1076-1078.
LUO S L,XU Z G,LIANG C Z.Compound trabeculectomy with conbercept for neovascular glaucoma［J］.Rec Adv Ophthalmol,2016,36(11):1076-1078.
［13］　黄萍,王雯倩,石砚,刘恩泽,张纯.贝伐单抗联合小梁切除术或睫状体光凝术治疗晚期新生血管性青光眼疗效比较［J］.中华实验眼科杂志,2015,33(4):362-366.
HUANG P,WANG W Q,SHI Y,LIU E Z,ZHANG C.Comparison of clinical efficacy between intravitreal bevacizumab combined with trabeculectomy and intravitreal bevacizumab combined with cyclophotocoagulation for late stage neovascular glaucoma［J］.Chin J Exp Ophthalmol,2015,33(4):362-366.
［14］　CHEN S,ZHOU M,WANG W,WU H M,YU X L,HUANG W B,et al.Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes［J］.Acta Ophthalmol,2015,93(7):e556-e560.
［15］　OHIRA S,INOUE T,SHOBAYASHI K,IWAO K,FUKUSHIMA M,TANIHARA H.Simultaneous increase in multiple proinflammatory cytokines in the aqueous humor in neovascular glaucoma with and without intravitreal bevacizumab injection［J］.Invest Ophthalmol Vis Sci,2015,56(6):3541.
［16］　ANDRS-GUERRERO V,PERUCHO-GONZLEZ L,GARCA-FEIJOO J,MORALES-FERNNDEZ L,SAENZ-FRANCS L,HERRERO-VANRELL R,et al.Current perspectives on the use of anti-VEGF drugs as adjuvant therapy in glaucoma［J］.Adv Ther,2017,34(2):378-395.
［17］　刘琳琳,王辉,蒋贻平,唐爱东,钟菲.联合抗VEGF药物的综合疗法治疗新生血管性青光眼的临床疗效［J］.眼科新进展,2018,38(1):72-75.
LIU L L,WAGN H,JIANG Y P,TANG A D,ZHONG F.The application of combined anti-VEGF medicine in the treatment of neovascular glaucoma［J］.Rec Adv Ophthalmol,2018,38 (1):72-75.
［18］　SUN Y Y,LIANG Y,ZHOU P,WU H J,HOU X R,REN Z Q,et al.Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term［J］.BMC Ophthalmology,2016,16(1):150.

相似文献/References:

[1]胡馨 王永毅 赵博.双切口联合手术治疗青光眼合并白内障临床疗效观察[J].眼科新进展,2012,32(4):000.
[2]田甜 刘伟 安琳 李丹丹 邢小丽 刘爱华 季健.晶状体前囊膜应用于兔眼超声乳化联合小梁切除术的实验研究[J].眼科新进展,2012,32(5):000.
[3]王勤 罗顺利.不同抗青光眼手术后浅前房发生率比较及原因分析[J].眼科新进展,2012,32(5):000.
[4]徐冰 董宁 肖林 褚利群 徐景美 王冰松.不同剂量曲安奈德前房注射抑制青光眼联合白内障手术后前葡萄膜炎的临床研究[J].眼科新进展,2012,32(6):000.
[5]马红利 李世洋 赵爱红 蒋骁男 陈萍.尿毒症血液透析继发新生血管性青光眼的治疗[J].眼科新进展,2012,32(8):000.
[6]刘海凤 朱晓谦 余涵.青光眼术后低角膜内皮细胞密度白内障手术26例临床分析[J].眼科新进展,2012,32(8):000.
[7]梁永强.超声乳化联合房角分离术与小梁切除术治疗原发性闭角型青光眼的疗效比较[J].眼科新进展,2013,33(2):000.
[8]李维娜 张育谋 李学喜 魏锐利.原发性急性闭角型青光眼持续性高眼压睫状体光凝后行小梁切除术的疗效观察[J].眼科新进展,2013,33(5):000.
[9]王建萍 马勇 薛雨顺 车选义 张德秀.小梁切除术后房水和晶状体中转化生长因子-β2含量的变化[J].眼科新进展,2013,33(10):000.
[10]谭思敏 李瑞庄 黎宗汉 方林彬.原发性青光眼滤过术后发生恶性青光眼的危险因素分析[J].眼科新进展,2013,33(12):000.

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-09-05